PURPOSE: There is renewed attention to primary site irradiation and local control for patients with high-risk neuroblastoma (NB). We conducted a retrospective review to identify factors that might predict for locoregional tumor control and its impact on overall survival. METHODS AND MATERIALS: Between July 2000 through August 2006, a total of 44 pediatric patients with NB received radiation therapy (RT) with curative intent using computed tomography (CT)-based treatment planning. The median age was 3.4 years and the median cumulative dose was 23.4 Gy. Overall survival and locoregional tumor control were measured from the start of RT to the date of death or event as determined by CT/magnetic resonance imaging/meta-iodobenzylguanidine. The influence of age at irradiation, gender, race, cumulative radiation dose, International Neuroblastoma Staging System stage, treatment protocol and resection status was determined with respect to locoregional tumor control. RESULTS: With a median follow-up of 34 months +/- 21 months, locoregional tumor progression was observed in 11 (25%) and was evenly divided between primary site and adjacent nodal/visceral site failure. The influence of locoregional control reached borderline statistical significance (p = 0.06). Age (p = 0.5), dose (p = 0.6), resection status (p = 0.7), and International Neuroblastoma Staging System stage (p = 0.08) did not influence overall survival. CONCLUSIONS: Overall survival in high-risk neuroblastoma is influenced by locoregional tumor control. Despite CT-based planning, progression in adjacent nodal/visceral sites appears to be common; this requires further investigation regarding target volume definitions, dose, and the effects of systemic therapy. Copyright 2010 Elsevier Inc. All rights reserved.
PURPOSE: There is renewed attention to primary site irradiation and local control for patients with high-risk neuroblastoma (NB). We conducted a retrospective review to identify factors that might predict for locoregional tumor control and its impact on overall survival. METHODS AND MATERIALS: Between July 2000 through August 2006, a total of 44 pediatric patients with NB received radiation therapy (RT) with curative intent using computed tomography (CT)-based treatment planning. The median age was 3.4 years and the median cumulative dose was 23.4 Gy. Overall survival and locoregional tumor control were measured from the start of RT to the date of death or event as determined by CT/magnetic resonance imaging/meta-iodobenzylguanidine. The influence of age at irradiation, gender, race, cumulative radiation dose, International Neuroblastoma Staging System stage, treatment protocol and resection status was determined with respect to locoregional tumor control. RESULTS: With a median follow-up of 34 months +/- 21 months, locoregional tumor progression was observed in 11 (25%) and was evenly divided between primary site and adjacent nodal/visceral site failure. The influence of locoregional control reached borderline statistical significance (p = 0.06). Age (p = 0.5), dose (p = 0.6), resection status (p = 0.7), and International Neuroblastoma Staging System stage (p = 0.08) did not influence overall survival. CONCLUSIONS: Overall survival in high-risk neuroblastoma is influenced by locoregional tumor control. Despite CT-based planning, progression in adjacent nodal/visceral sites appears to be common; this requires further investigation regarding target volume definitions, dose, and the effects of systemic therapy. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Mary Lou Schmidt; Ashutosh Lal; Robert C Seeger; John M Maris; Hiroyuki Shimada; Maura O'Leary; Robert B Gerbing; Katherine K Matthay Journal: J Clin Oncol Date: 2005-08-22 Impact factor: 44.544
Authors: Rani E George; Shuli Li; Cheryl Medeiros-Nancarrow; Donna Neuberg; Karen Marcus; Robert C Shamberger; Michael Pulsipher; Stephan A Grupp; Lisa Diller Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: K K Matthay; J G Villablanca; R C Seeger; D O Stram; R E Harris; N K Ramsay; P Swift; H Shimada; C T Black; G M Brodeur; R B Gerbing; C P Reynolds Journal: N Engl J Med Date: 1999-10-14 Impact factor: 91.245
Authors: Karen J Marcus; Robert Shamberger; Heather Litman; Daniel von Allmen; Stephen A Grupp; Cheryl Medeiros Nancarrow; Joel Goldwein; Holcombe E Grier; Lisa Diller Journal: J Pediatr Hematol Oncol Date: 2003-12 Impact factor: 1.289
Authors: B Kremens; T Klingebiel; F Herrmann; C Bender-Götze; S Burdach; W Ebell; W Friedrich; E Koscielniak; H Schmid; W Siegert Journal: Med Pediatr Oncol Date: 1994
Authors: Daphne A Haas-Kogan; Patrick S Swift; Michael Selch; Gerald M Haase; Robert C Seeger; Robert B Gerbing; Daniel O Stram; Katherine K Matthay Journal: Int J Radiat Oncol Biol Phys Date: 2003-05-01 Impact factor: 7.038
Authors: E Stanton Adkins; Robert Sawin; Robert B Gerbing; Wendy B London; Katherine K Matthay; Gerald M Haase Journal: J Pediatr Surg Date: 2004-06 Impact factor: 2.545
Authors: Matthew J Ferris; Hasan Danish; Jeffrey M Switchenko; Claudia Deng; Bradley A George; Kelly C Goldsmith; Karen J Wasilewski; W Thomas Cash; Mohammad K Khan; Bree R Eaton; Natia Esiashvili Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-27 Impact factor: 7.038
Authors: Ji Hwan Jo; Seung Do Ahn; Minji Koh; Jong Hoon Kim; Sang-Wook Lee; Si Yeol Song; Sang Min Yoon; Young Seok Kim; Su Ssan Kim; Jin-Hong Park; Jinhong Jung; Eun Kyung Choi Journal: Radiat Oncol J Date: 2019-09-30